BRIEF-Hutchison China MediTech, Innovent Expand Collaboration On Sintilimab & Surufatinib

Oct 10 (Reuters) - Hutchison China MediTech Ltd:

* INNOVENT AND CHI-MED EXPAND GLOBAL COLLABORATION

* INNOVENT AND CHI-MED EXPAND GLOBAL COLLABORATION TO EVALUATE COMBINATION OF SINTILIMAB AND SURUFATINIB IN SOLID TUMORS

* EXPANSION TO ALLOW INNOVENT, CO TO EXPLORE POTENTIAL APPLICATION OF TYVYT, SURUFATINIB COMBINATION THERAPY IN SOLID TUMORS

* EXISTING COLLABORATION WITH INNOVENT ON FRUQUINTINIB IS PROGRESSING WELL

* CLINICAL STUDIES WITH NEW COMBINATION WILL BE CONDUCTED BOTH IN UNITED STATES AND IN CHINA. Source text for Eikon: Further company coverage: